Who invested in Attomarker

2 rounds we have observed, with the 0 investors named in them. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Raised 10 months ago

Follow Attomarker and see its new rounds in your feed.Start following

Funding summaryUpdated 31 Oct 2026

$4.8Mraised across 2 rounds since 2025, from 2 sources

$1.8MRound$3.0MRound

Latest round: Round, $3.0MJan 2026
Step-upi: 1.7×
Investors: 0

See who backed them

The funding story

Each circle is a round, placed by date and sized by amount. The line above is the running total.

2026

$1.8MRound$3.0MRound

First round: Round, $1.8M
Biggest round: $3.0M
Between rounds: 10 months

The rounds

Jan 2026
Round$3.0M
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet
Mar 2025
Round$1.8M
No investor was named in the report.
Shares issued, filed with Companies House (SH01); no report of this raise yet

Funding filed with regulators

Attomarker filed 3 raises, $4.8M in all. Filings say how much was sold and to how many investors; they never name the investors.

Jan 2026$3.0MUK share allotment
Apr 2025$1.6MUK share allotment
Mar 2025$243KUK share allotment

Founders and team

From Attomarker's own website: 1 founder, 4 on the team.

Prof. Andrew ShawCEO & Founder

Andrew VincentChief Marketing Officer
Chandru R. ChandrasekarDirector of International Development
Dr Philip James-PembertonDirector of Research
Dr Shivali KohliDirector of Products

AdvisersSteve BrineYves Le Goff

Also claim to have backed them

This firm lists Attomarker as a portfolio company on their own website, but no report of a round names it. They are the firms' own claims, kept apart from the rounds above.